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Genetic loss of VGLUT3 in cochlear inner hair cells results in profound deafness. In this issue of Neuron,
Akil et al. (2012) show that AAV-mediated introduction of wild-type VGLUT3 in the genetically deaf mouse
cochlea results in significantly improved hearing.Genetic forms of sensorineural deafness
account for almost half of all patients with
hearing loss (Shearer et al., 2011). Current
therapies for sensorineural hearing loss
are based primarily on amplification with
hearing aids or, if the deficit is severe to
profound, surgical placement of cochlear
implants. In recent years, a large and ever
increasing number of genes whose muta-
tions cause human deafness have been
identified, thereby drastically enhancing
the diagnostic capabilities for individuals
with hearing loss (Lenz and Avraham,
2011). Knowledge of the underlying
molecular geneticmechanisms that cause
hearing loss also raises the possibility for
novel therapeutics, such as those based
on gene transfer and related methods
that influence gene expression in affected
tissues. For example, replacement of
a defective or absent gene product,
or removal and/or repair of products of
dominant negative mutations, might be
predicted to correct the underlying pathol-
ogies caused by specific gene mutations.
A successful approach for the latter type
of therapy was recently accomplished
for a dominant-negative mutation of the
GJB2 gene, which encodes the gap junc-
tion protein Connexin 26 (Cx26) (Maeda
et al., 2005; Richard et al., 1998). Maeda
et al. (2005) showed that siRNA-mediated
downregulation of this dominant-negative
GJB2 mutation partially improved hearing
in mouse ears that model this mutation.
These earlier studies on Cx26 showed
that manipulation of a mutant protein can
be achieved without compromising
optimal levels of the normal protein, a crit-
ical requirement for successful translation
of this approach to humans.188 Neuron 75, July 26, 2012 ª2012 ElsevierNow there is evidence presented by
Akil et al. (2012) in this issue of Neuron
that further supports the promise of
gene therapy approaches to improving
hearing health. Unlike the Maeda study
that used a mouse model of a dominant-
negative mutation, Akil et al. (2012) report
a pioneering treatment of a mouse with
a gene deletion (Seal et al., 2008). They
show that replacement of an absent
gene (VGLUT3) by viral-mediated inser-
tion of the wild-type gene into VGLUT3
knockout mouse ears can rescue struc-
tural and functional hearing loss pheno-
types. Results presented in their paper
are a true breakthrough because they
show that gene therapy can lead to func-
tional recovery from sensorineural deaf-
ness. Even more exciting is the direct
relevance of this work to a large popula-
tion of humans who have mutations in
the VGLUT3 gene (Ruel et al., 2008).
Vglut3 encodes a vesicular glutamate
transporter that is essential for transport-
ing the neurotransmitter glutamate into
secretory vesicles (Takamori et al., 2002).
In mice lacking VGLUT3 in the inner hair
cells, hearing is absent because the
neurotransmitter glutamate is not re-
leased by inner hair cells and auditory
neurons do not depolarize in response to
sound (Seal et al., 2008). Akil et al.
(2012) used adeno-associated virus type
1 (AAV1) to insert the wild-type mouse
Vglut3 gene into cochlear cells (Figure 1).
Interestingly, after viral infection, most
cells in the cochlea expressed the green
fluorescent protein (GFP) reporter con-
struct, whereas only hair cells expressed
the newly introduced VGLUT3 pro-
tein. Infected ears demonstrated nearlyInc.complete rescue of auditory function,
based on electrophysiological measure-
ments by auditory brainstem response
(ABR). Significant yet partial improvement
was also noted in the morphology of the
synaptic region as well as in other physio-
logical and behavioral measures of
hearing, predicting potentially exciting
future clinical benefits. Morphological
rescue of the synaptic ribbon area, where
inner hair cells connect with auditory
nerve terminals, provided a possible
structural explanation for the ac-
companying functional improvement
(Figure 1). Mutant mice without treatment
also displayed a partial degeneration of
auditory neurons. AAV1-VGLUT3 treat-
ment did not prevent this degeneration,
but remaining auditory neurons were
nevertheless sufficient to facilitate ade-
quate hearing thresholds. Long-term
follow-up of infected ears showed that
rescue of hearing ability was stable until
a relatively late age in themice (9 months),
suggesting that the therapy may result
in permanent structural and functional
repair.
Application of gene replacement
therapy to treatment of deafness appears
relatively simple and attractive for several
reasons. Introduction of the normal (wild-
type) protein into hair cells, in which its
function is critical for hearing (and its
absence causes deafness), is a compel-
ling approach for effectively and perma-
nently treating genetic forms of deafness.
Such approaches have been under con-
sideration for some time, with phenotypic
rescue for deafness by gene replacement
first shown in 1998, when researchers
rescued the DFNB3 deafness mouse
Figure 1. Cartoon Showing the Organ of Corti Inner and Outer Hair Cells
The typical inner hair cell connects to auditory nerve fibers and depolarizes them by releasing glutamate upon sound activation. Shown to the right of the hair cell
are schematic drawings of the ribbon synapse as seen by electron microscopy. In Vglut3mutant mice, VGLUT3 is absent, the ribbon and neurotransmitter vesi-
cles appear pathological (the ribbon is flat and vesicles are elongated), and hearing is impaired (the musical notes depict hearing ability or lack thereof). In Vglut3
mutant mice treated with AAV1-mediated Vglut3 gene transfer, VGLUT3 can be detected in inner hair cells, and both the ribbon and the vesicles more closely
resemble the normal morphology. Mice treated with AAV-Vglut3 exhibit normal hearing thresholds as measured by electrophysiology and also exhibit hearing
using behavioral assays.
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rial artificial chromosome (BAC) with the
wild-type gene (Probst et al., 1998).
However, transgenic methods such as
BAC insertion are not feasible in humans,
for both practical and ethical reasons. In
contrast, the approach used by Akil
et al. (2012) is conceptually relevant to
clinical applications. Theoretically, viral
infection for inserting a wild-type gene
could be used to reverse mutant pheno-
types when hair cells or other critical cell
populations survive yet do not function
normally, such as with VGLUT3mutations
in humans and mice.
Several technical advances have been
made in this study that put us closer
to seeing successful gene therapy in
humans. Use of AAV apparently provides
long-term expression, with minimal or no
side effects attributed to viral infection.
Expression of the reporter gene, GFP,
occurred throughout the infected co-
chlear tissue but VGLUT3 expression
was restricted to inner hair cells, suggest-
ing that posttranslational mechanisms
can act on exogenously introduced DNA
to regulate tissue-specific gene expres-
sion. The broader implications of thisprecise level of gene regulation are that
concerns about tissue or cell type-
specific targeting may be more easily
overcome than previously suspected.
A key concern associated with viral-
mediated gene transfer is gene dosage,
because the amount of gene product
produced and the extent to which the
cell can regulate it may vary widely.
Results by Akil et al. (2012) suggest that
the levels of VGLUT3 produced by the
AAV were compatible with phenotypic
rescue, providing hope that adequate
levels of protein synthesis may be
achieved in humans by this method. How-
ever, gene products relevant for other
gene mutations may be more sensitive
to gene dosage, such that gene replace-
ment therapy strategies will need to be
developed specifically for each mutation.
Despite the excitement raised by this
study, several milestones will need to be
reached before this approach can be
used in humans. First, proof that this
method works in mature ears needs to
be provided. Akil et al. (2012) used mouse
pups that were 1–3 or 10–12 days old,
both ages in which the mouse auditory
system is still immature. The researchersNeurondetermined that the phenotypic rescue
worked better in the younger mice, which
may suggest that the current method is
less effective in truly mature tissues
(P21 and later for the mouse cochlea).
The decreased efficacy in older animals
could reflect the maturity of hair cells or
surrounding cells and tissues (leading
to reduced plasticity), development of
immune memory, or as-yet-undefined
changes in the inner ear. Second, for
applicability to human therapies, it may
be necessary to correct most if not all
aspects of the relevant underlying pathol-
ogies causing the deafness. For example,
Akil et al. (2012) observed ongoing loss of
spiral ganglion neurons, despite func-
tional and structural improvements in
the treated hair cells. Ongoing neuronal
degeneration would probably degrade
long-term correction of inner ear defects
and would need to be addressed for opti-
mal treatment of patients with VGLUT3
mutations.
Despite these limitations, the possibili-
ties raised by this study warrant high
enthusiasm. For individuals with heredi-
tary hearing loss who are currently treated
with cochlear implants, there is reason to75, July 26, 2012 ª2012 Elsevier Inc. 189
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lead to the development of significantly
better, more specifically targeted thera-
pies to correct their hearing. Gene
therapy-based approaches will probably
become relevant to genetic forms of
hearing loss in which the underlying cells
or proteins can be identified, especially
in cases in which critical cells and tissues
survive until the age at which gene trans-
fer protocols can be used. It would be
truly groundbreaking if similar phenotypic
rescue could be developed to treat some
of the more common forms of hereditary
deafness, such as those caused by the
most prevalent forms of Connexin gene
mutations, which collectively account for
more than half of all cases of human
hereditary deafness (Cryns and Van
Camp, 2004). It is also reasonable to
predict that the successful treatment190 Neuron 75, July 26, 2012 ª2012 Elsevierapproach reported in the VGLUT3 deaf-
ness mouse model could establish a
framework for assessing the potential for
gene replacement therapies for other
senses and other hereditary neurological
disorders. Finally, the results of this study
may also help pave the way for personal-
ized, gene-informed, targeted therapies
that improve health for individuals with
other Mendelian disorders. In case you
have not heard, the future is now.REFERENCES
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In a theoretical study in this issue of Neuron, Gidon and Segev (2012) identify several new principles govern-
ing how inhibition interacts with excitation in active dendrites. They show that inhibitory synapses can
interact with excitability at a distance, effectively ‘‘throwing their voices’’ in the dendritic tree, such that
distributed inhibitory synapses can act synergistically to provide a global veto of dendritic excitability.The interplay between inhibition and
excitation has fascinated neurophysiolo-
gists at least since Sherrington (1932)
proposed that it forms the basis of the
operation of the nervous system. Over
the last 80 years, numerous functional
roles have been proposed for inhibition,
including regulation of timing, gain
control, sharpening of tuning, and stabili-
zation of ongoing activity in recurrent
neural circuits (Isaacson and Scanziani,
2011). In addition, anatomical evidence
has accumulated showing that principal
neurons receive thousands of inhibitorysynaptic contacts, made by distinct
subtypes of inhibitory interneurons which
target specific domains on the dendritic
tree and which may also have distinct
functional roles. And yet, the traditional
view of how inhibitory synapses influ-
ences the output of a neuron has
been dominated by a ‘‘somatocentric’’
perspective, in which the effect of inhibi-
tory inputs is measured by their ability to
control somatic membrane potential and
the frequency of action potentials initiated
in the axon. This classical perspective is
based on the passive cable properties ofdendrites, which result in spatial attenua-
tion of membrane potential changes and
even steeper attenuation of the visibility
of a synaptic conductance with distance
from the synapse (Koch et al., 1990). It’s
all about location, location, location: the
conductance change induced by a single
inhibitory synapse remains highly local
and reaches its maximum at the site of
the synapse, while the best place for an
inhibitory synapse to act as a gatekeeper
and control the influence of an excitatory
synapse on neuronal output is ‘‘on the
direct path’’ from the excitatory synapse
